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Letters to the EditorReply to: ‘‘Dendritic cell subset composition in the human liver
is more complex than it seems’’To the Editor:
We read with interest the letter from Strauss and Bartlett regard-
ing our study of Dendritic Cells (DCs) in healthy human liver [1]
and would like to develop several of the points they raise. CD141
is a type 1 membrane receptor that binds thrombin and is nor-
mally expressed by endothelial cells [2]. Its role on the surface
of immune cells remains a puzzle and the functional relevance
of variable expression by subsets of DCs is not known. DCs
obtained from some organs, e.g., the skin, express CD141 on both
CD14 and CD14+ subsets of antigen presenting cells [3]. How-
ever, the majority of liver DCs expressing CD141 are CD11c+
and CD14 [1,3]. In addition, neither CD123+ plasmacytoid DCs
nor CD1c+ myeloid DC subsets appear to express high levels of
CD141 in the liver [1]. Extensive functional analyses of these sub-
sets are required before the puzzle can be solved, a particularly
challenging task given the small numbers of cells and difﬁculty
of getting healthy human tissue.
For functional characterisation of hepatic CD141+ DCs we
used a magnetic bead isolation method which was chosen in
order to maximize yield and limit activation or contamination
due to ﬂow sorting, as did Lauterbach et al., 2010 [4] for their
demonstration of IFN-k production from blood CD141+ DCs. To
increase purity, we ran our samples over two columns as per
manufacturer instructions, resulting in cell populations that were
highly enriched for CD141+ cells. (High CD141 expressing DCs are
clearly distinguishable from low CD141 expressors in the
immuno-ﬂuorescence image in Fig. 2A, which is of a mixed pop-
ulation of liver immune cells.)
Since we began this work, the CLEC9a marker was established
as a useful marker of DC subsets when used together with CD141
and we found that the CD141 high population of DCs in the liver
also co-expressed CLEC9a. Future work on this population of cells
would be best served by isolation of double positive
CD141+CLEC9a+ cells. Complete characterisation of the entire1098 Journal of Hepatology 20
Open access under CC BY-NC-ND license.antigen-presenting cell repertoire of the liver may well require
addition of even more immune cell markers.
Use of liver perfusate as a source of liver resident APCs cer-
tainly has its limitations. We may well be studying cell popula-
tions that have higher migratory properties than others. We
observe lower frequencies of iNKT cells in liver perfusate (unpub-
lished data) compared to what we [5] and others have found in
liver biopsies, suggesting that this particular population is less
migratory than conventional NK cells. However there is still no
ideal method for the study of minor cell subsets from healthy
human liver tissue. Too many markers are required to accurately
deﬁne DC subsets to use immunohistochemistry. Digestion of tis-
sue prior to ﬂow cytometry may also skew results, if, as previ-
ously demonstrated [6], certain epitopes are sensitive to
digestion enzymes. Also rare cell subsets may be lost in the mul-
tiple washing steps required in such methods. DCs are at too low
frequency to study in liver biopsies and they are unlikely to be
normal if obtained from tumour bearing liver tissue as signiﬁcant
differences in iNKT, and monocyte populations as well as cyto-
kine levels [7–9] have been found in liver tissue from patients
undergoing resection when compared with healthy liver. More-
over, it has recently been demonstrated that tumour microenvi-
ronment profoundly suppresses DC function [10]. Perhaps DC
subset distribution and function in healthy liver tissue may be
better explored using alternative methods in centres where ade-
quate tissue might be obtained, e.g., during resizing of liver for
paediatric transplantation.
It is clear that the CD141+ population of DCs is heterogeneous
as evidenced by differing expression of ILT3 and ILT4 [1]. The
presence of these subsets in both healthy and diseased livers
warrants further study. While some liver resident DCs may be
tolerogenic, our work clearly illustrates the ability of CD141+
DCs from healthy human liver to secrete inﬂammatory cytokines
and drive T cell responses. These proinﬂammatory liver resident14 vol. 60 j 1097–1103
ogy 2012;1:751–753.
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APCs are good targets for development of vaccine adjuvants or
immunotherapy.
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To the Editor:
We read with great interest the recently published review by
Romero-Gòmez and colleagues concerning the management of
anemia induced by triple therapy in patients with chronic hepa-
titis C [1]. In their work, authors thoroughly discuss about path-
ophysiological mechanisms responsible for the anemia observed
during triple therapy with telaprevir or boceprevir, remark base-
line and on-treatment factors predictive of more severe anemiza-
tion, and propose a sequential strategy to manage anemia based
ﬁrst on ribavirin dose reduction and then on epoetin administra-
tion. We strongly agree with the authors that anticipation of
anemia, which is based mainly on the knowledge of predictive
factors, is among the essential requisites for a tailored approach
to patient monitoring and management. In this regard, we
consider that the issue of a possible renal impairment during tri-
ple therapy with telaprevir or boceprevir, which is associated
with a more severe degree of anemia, deserved to be mentioned
in an updated review on this item. Indeed, simultaneously or
right after the publication of the work by Romero-Gòmez et al.,
several papers have been published concerning a possible renal
impairment during triple therapy with telaprevir or boceprevir
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[2–5]. While a decline of renal function was not reported as a
safety issue in clinical trials with any of the two drugs [6–9],
cases of renal failure were ﬁrstly signaled in the French early
access program [10]. More recently, in a large cohort of patients
undergoing triple therapy, Mauss et al. reported a week 12 inci-
dence of renal insufﬁciency stage 3, i.e., estimated glomerular ﬁl-
tration rate (eGFR) <60 ml/min, of 6.6% in patients treated with
telaprevir and of 4.7% in patients treated with boceprevir [2].
Patients with a drop of eGFR <60 ml/min had a higher absolute
decrease in hemoglobin and a lower week 12 hemoglobin level
[2]. Independently from the development of overt renal failure,
Kapelusznik et al. reported a mean maximal change of eGFR of
22 ml/min with respect to baseline in a group of 72 patients
analyzed at different time points during triple therapy with boce-
previr [3], Fukuda et al. observed a rapid decline of eGFR in 25
patients in triple therapy with telaprevir [baseline: 84.8, week
1: 69.9 ml/min, p <0.001] [4], and Karino et al. reported an almost
identical mean drop of eGFR at week 1, which was substantially
stable at the subsequent time points, in 68 patients in triple
therapy with telaprevir [baseline: 85.8, week 1: 69.6, week 4:
69.2, week 12: 72.5 ml/min] [5]. In the latter study, at week 1,
vol. 60 j 1097–1103 1099
